Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $23.57 Average Target Price from Brokerages
Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been given a consensus rating of “Buy” by the ten analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $23.57.
A number of equities analysts have recently issued reports on HALO shares. BMO Capital Markets raised Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $17.00 to $24.00 in a research note on Thursday, January 9th. BidaskClub downgraded Halozyme Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 1st. Piper Sandler raised Halozyme Therapeutics from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $18.00 to $27.00 in a research note on Wednesday, February 5th. ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, February 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price objective (up from $27.00) on shares of Halozyme Therapeutics in a research note on Monday, January 27th.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Chevy Chase Trust Holdings Inc. purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $27,000. Quadrant Capital Group LLC purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $35,000. Quantbot Technologies LP increased its stake in Halozyme Therapeutics by 156.1% in the 4th quarter. Quantbot Technologies LP now owns 2,561 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 1,561 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its stake in Halozyme Therapeutics by 25.2% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,800 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 967 shares in the last quarter. Finally, US Bancorp DE increased its stake in Halozyme Therapeutics by 25.8% in the 4th quarter. US Bancorp DE now owns 5,088 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 1,043 shares in the last quarter. 85.33% of the stock is owned by hedge funds and other institutional investors.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.05). The business had revenue of $46.20 million for the quarter, compared to analysts’ expectations of $54.96 million. Halozyme Therapeutics had a negative return on equity of 15.76% and a negative net margin of 19.73%. The business’s quarterly revenue was up 80.5% on a year-over-year basis. During the same period last year, the company posted ($0.19) earnings per share. As a group, analysts predict that Halozyme Therapeutics will post -0.45 EPS for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Recommended Story: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.